Related Experiment Video
Updated: May 6, 2026

Immunohistochemical Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine in Developing and Postmitotic Mouse Retina
Published on: August 29, 2018
WTAP mediated m6A methylation modulates retinal photoreceptor function via facilitating of REEP6, PDE6B and RDH12
Kuanxiang Sun1,2, Lin Zhang1, Wenjing Liu1
1The Sichuan Provincial Key Laboratory for Genetic Diseases and Center for Medical Genetics, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Abstract:
Inherited retinal dystrophies (IRDs) are a leading cause of visual impairment and irreversible blindness worldwide, yet their precise molecular and genetic mechanisms remain unclear. N6-1ent. In the mammalian retina, m6A methylation is widely distributed in various cellular layers and is essential for retinal homeostasis. In this study, we assessed the in vivo roles of WTAP, a crucial component of the m6A methyltransferase complex, in the mammalian retina and demonstrated that loss of Wtap led to diminished scotopic ERG responses, progressive retinal degeneration, and significant loss of rod cells in mice. Wtap deficiency drastically reduced global m6A levels in the retina due to abolished WTAP-mediated stability of the methyltransferase complex. Mechanistically, absence of WTAP disrupts m6A modification of phototransduction-related genes and specifically causes the epigenetic silencing of PDE6B, REEP6, and RDH12. Detailed analysis further revealed that WTAP facilitated the translation of Reep6, Pde6b, and Rdh12 through modulating m6A deposition in 3'UTR of mRNAs. Moreover, reintroduction of WTAP in affected retinas, through crossing with CAG-Wtap mouse line or AAV-mediated gene therapy, partially restored expression of PDE6B, REEP6, and RDH12 and finally mitigated retinal degeneration. Collectively, our study highlights critical roles of WTAP in photoreceptor function and survival, thus providing novel therapeutic strategies for IRDs.

